A new study identified the potential use of two diagnostic markers for ischemic heart disease.
Syrris has upgraded its range of Atlas automated synthesis systems, adding stainless steel reactors and a high temperature upgrade kit.
Redd & Whyte has launched the Preddator S1, an instrument designed for successful dispensing of low volumes of cells, beads, and biochemical reagents into 96- to 3456-well plates.
FEI Company released a set of software applications that increase the throughput and ease-of-use of its electron microscopes for biological research.
Generex Biotechnology Corporation has created a scientific advisory board in an effort to further its drug development programs, specifically in the areas of oncology and metabolic diseases.
MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived, fully human antibody in the therapeutic area of ophthalmology.
Within 24 hours of culturing adult human stem cells on a new type of matrix, University of Michigan researchers were able to make predictions about how the cells would differentiate, or what type of tissue they would become
A new tool to excavate bacterial genomes that potentially hide a rich array of pharmaceutical treasures has led to the discovery of a novel antibiotic.
PROLOR Biotech, Inc. reported publication of a preclinical studyshowing that human growth hormone (hGH) linked to PROLOR’s carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH.
Cornerstone Therapeutics Inc. has acquired a license to acquire intellectual property from Alitair Pharmaceuticals, Inc.
Researchers at Carnegie Mellon University have developed a new fluorescent biosensor that could aid in the development of an important class of drugs that target a crucial class of proteins called G protein-coupled receptors.
According to a new study, the cause of brain cell death in cases of Alzheimer's disease, Parkinson's disease, and Huntington's disease may be the untimely transfer of nitric oxide from one protein to another.
Novartis Vaccines has started shipping seasonal influenza vaccine to U.S. customers for the 2010-2011 season, allowing health care professionals to initiate protection of their patients well in advance of this year’s flu season.
Optimer Pharmaceuticals, Inc. announced that it has submitted a Marketing Authorization Application for fidaxomicin to the European Medicines Agency under the European Union’s Centralized Procedure.
Drugmaker Merck & Co. reported a 52% drop in second-quarter net income, weighed down by big restructuring charges from buying Schering-Plough Corp., generic competition and other factors.